In the claims:

Please add new claims 146-147 and amend claims 17, 21-23, 107 and 111-113, without prejudice, as follows:

17. (Amended) A procoagulant-active FVIII protein comprising a human FVIII polypeptide that is modified, wherein the modification comprises a deletion of the B domain, a deletion of the von Willebrand factor binding site, a mutation at Arg740 and an addition of an amino acid sequence spacer between the A2- and A3- domains[.], wherein the amino acid sequence spacer is of a sufficient length so that upon activation, the procoagulant-active FVIII protein becomes a heterodimer.

21. (Amended) The protein of Claim 17, wherein the amino acid sequence spacer is 54 amino acid residues in length.

22. (Amended) The protein of Claim 21, wherein the amino acid sequence spacer [comprises] consists of amino acid residues 741 to 794 of wild-type FVIII, wherein the amino acid residue at position 794 is selected from the group consisting of threonine and leucine.

23. (Amended) The protein of Claim 22, wherein the amino acid residue at position 794 is threonine.

107. (Amended) A procoagulant-active FVIII protein comprising a human FVIII polypeptide that is modified, wherein the modification consists of a deletion of the B domain, a deletion of the von Willebrand factor binding site, a mutation at Arg740 and an addition of an amino acid sequence spacer between the A2- and A3- domains[.], wherein the amino acid sequence spacer is of a sufficient length so that upon activation, the procoagulant-active FVIII protein becomes a heterodimer.

111. (Amended) The protein of Claim 107, wherein the amino acid sequence spacer is 54 amino acid residues in length.